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ABSTRACT 
Objective: To obtain an optimum and validated method for analyzing lercanidipine in plasma using Ultra Performance Liquid Chromatography of 
Tandem Mass Spectrometry (UPLC-MS/MS).  
Methods: The separation was carried out using 1.7μm (2.1 x 100 mm) Waters AcquityTM UPLC C18 column, a mobile phase of the 0.1% formic acid-
methanol mixture (20:80 v/v) with isocratic elution, 30 °C column temperature, 0.2 ml/min flow rate and amlodipine as an internal standard. Mass 
detection was performed with a positive XBL TQD type Electrospray Ionization (ESI) in Multiple Reaction Monitoring modes. Lercanidipine was detected 
at m/z value of 612.11>280.27 and amlodipine was detected at m/z value 409.1>238.15. The optimum sample preparation method was a liquid-liquid 
extraction using 5 ml of n-hexane-ethyl acetate (50:50 v/v), vortex mixed for 3 min, centrifuged at 4000 rpm for 20 min, evaporated with nitrogen at 50 
°C for 30 min, and the residue was reconstituted with 100 μl of mobile phase.  
Results: The method was linear in the range of 0.025-10 ng/ml with r ≥ 0.9986. Accuracy and precis ion within-run and between-run met the 
requirements with %diff and %CV, not exceeding ± 15% and not more than ± 20% for Lower Limit of Quantification (LLOQ) concentration.  
Conclusion: It was concluded that the developed method met the requirements of selectivity, carry over, stability, the integrity of dilution, and matrix 
effects under the Guideline on Bioanalytical Method Validation by the European Medicines Agency in 2011. 
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Lercanidipine is effective for the treatment of patients with mild to 
moderate hypertension without affecting heart rate [1]. As an 
antihypertensive derivative of calcium channel blockers used in 
serious conditions, lercanidipine is included on the bioequivalence test 
mandatory drug list [2]. Implementation of bioequivalence tests must 
be using validated bioanalysis methods [3] therefore a reliable, rapid, 
and highly sensitive bioanalytical measurement technique for plasma 
drug measurement is required. 
Ultra High-Performance Liquid Chromatography (UPLC) is a rapid 
separation technique with higher chromatographic efficiency than 
High-Performance Liquid Chromatography (HPLC) [4].  
In a previous study, LLOQ was obtained at 0.1 ng/ml with a solid phase 
extraction method using UPLC-MS/MS, and 1.66 ng/ml of Cmax 
lercanidipine was obtained from healthy subjects [5]. The objective of 
this research is to obtain an optimum and validated method for analyzing 
lercanidipine in plasma using Ultra Performance Liquid Chromatography 
of Tandem Mass Spectrometry (UPLC-MS/MS). Hence this research 
developed lercanidipine analysis method using UPLC-MS/MS to obtain 
0.05 ng/ml LLOQ, in accordance with the requirements of Guideline on 
Bioanalytical Method Validation by the European Medicines Agency in 
2011 that LLOQ is no more than 5% Cmax [6, 7]. 
MATERIALS AND METHODS 
Equipment 
Ultra high performance liquid chromatography (Waters Xevo TQD 
Triple Quadrupole) consisting of Quartenary Solvent Manager (Acquity 
UPLC H-Class), Sample Manager (Acquity UPLC), Nitrogen generator 
compressor (PEAK Scientific), UPLC Acquity column BEH C18 (100 mm 
x 2.1 mm) 1.7 μm, a triple quadrupole (Xevo TQD) mass analyzer with 
an ionization source (ZsprayTM). 
Materials 
Lercanidipine (Hetero Drugs Limited); amlodipine (Dr. Reddy's 
Laboratories Limited); aquabidest (Ikapharmindo); methanol, 
acetonitrile; formic acid; ammonium formate; n-hesana; ethyl acetate; 
and dichloromethane were purchased from Merck; Plasma samples 
(Indonesian Red Cross). 
Stock solution 
5.0 mg lercanidipine was weighed and dissolved with methanol to 
obtain a concentration of 1.0 mg/ml (1000 ppm). 5.0 mg amlodipine as 
the internal standard was weighed and dissolved with methanol to 
obtain a concentration of 1.0 mg/ml (1000 ppm). Dilution was done to 
obtain a solution with a certain concentration.  
Optimization of lercanidipine analysis used ultra-high 
performance liquid chromatography-tandem mass spectrometry 
Initial optimization was done on the mass spectrometry. The standard 
solution of lercanidipine 10.0 μg/ml and amlodipine 10.0 μg/ml each 
of 1 ml were added to the reservoir. Then the standard solution was 
dispensed into mass spectrometry. During the standard solution, the 
measurements of mass spectrometry parameters are the tension in the 
capillary tube, dissolved gas temperature, dissolved gas flow rate, the 
flow rate at cone, the voltage at cone, source temperature, ions energy, 
collision energy, and m/z ratio on each compound.  
The optimization of chromatographic conditions was conducted by 
injecting a mixture of 1.0 μg/ml lercanidipine and 1.0 μg/ml of 
amlodipine into the UPLC-MS/MS system and the chromatographic 
response was observed. Optimization began with the selection of 
combination and comparison of the mobile phase, then carried out the 
optimization of mobile phase and column temperature. The optimization 
was carried out with 2.0 mmol ammonium formate in water (pH 2.5; 
formic acid buffer)-acetonitrile (5:95 v/v; 10:90 v/v; 15:85 v/v; 20:80 
v/v; and 30:70 v/v); 0.1% formic acid-acetonitrile (10:90 v/v; 20:80 v/v; 
and 30:70 v/v); and 0.1% formic acid-methanol (5:95 v/v; 10:90 v/v; 
20:80 v/v; and 30:70 v/v). Variations in the optimization of the flow rate 
of the mobile phase were 0.2 ml/min and 0.3 ml/min. The column 
temperature was optimized at 25 °C; 30 °C; and 40 °C. 
Optimization of sample preparation 
In this research, the sample preparation used liquid-liquid extraction. 
As much as 500 μl mixture of lercanidipine in plasma with a certain 
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concentration was added with 25 μl of the internal standard (100 
ng/ml). Then the mixture was extracted with 5 ml of extraction 
solution with the following variations: 100% hexane, 100% ethyl 
acetate, hexane-ethyl acetate (50:50 v/v), and 100% dichloromethane. 
The mixture was vortexed, optimized for 1, 2, and 3 min and 
centrifugation optimization was performed for 5, 10, 15, and 20 min at 
4000 rpm. Then the organic phase was separated and evaporated with 
nitrogen at 50 °C for 30 min, the residue was reconstituted with 100 μl 
of the mobile phase. Finally, 10 μl of the aliquot was injected into the 
chromatography system. 
Validation of lercanidipine in plasma 
The full validation of lercanidipine analysis method in plasma was 
performed with parameters such as selectivity, carry over, LLOQ, the 
linearity of calibration curve, accuracy and precision, recovery, dilution 
integrity, matrix effect, and stability. 
RESULTS AND DISCUSSION 
Optimization of lercanidipine using liquid chromatography-
tandem mass spectrometry 
Detection of lercanidipine in mass spectrometry using positive ESI 
ionization of Multiple Reaction Monitoring (MRM) type was performed 
with several ionization parameters such as a capillary voltage of 3.0 kV, 
desolvation temperature of 250 °C, desolvation of 594 L/h, flow rate at 
cone 1 L/h, voltage at cone 50 V, source temperature of 148 °C. The ion 
energy was 0.2 and collision energy was 20 V. Lercanidipine was 
detected at m/z ratio 612.18>280.27 while amlodipine detected at 
409.1>238.15. The chromatography condition of lercanidipine analysis 
was conducted using the column of Acquity UPLC BEH C18 (100 mm x 
2.1 mm);1.7 μm; with mobile phase consist of 0.1% formic acid-
methanol (20:80 v/v); flow rate of 0.2 ml/min; column temperature 
was 30 °C; and amlodipine as internal standard.  
Optimization of sample preparation 
The optimum sample preparation was obtained by extraction of 500 
µL plasma containing lercanidipine and amlodipine with 5 ml of n-
hexane-ethyl acetate (50:50 v/v), then vortexed for 3 min and 
centrifuged for 20 min at 4000 rpm. The organic phase was separated 
and evaporated with nitrogen gas at 50 °C for 30 min, then the residue 
was reconstituted with 100 μl of the mobile phase. Afterwards 10 μl of 
the aliquot was injected into the chromatography system. 
Selectivity 
The selectivity was performed on LLOQ concentrations and plasma 
blanks using six different plasma sources. The results show that there 
was no interference or impurity on the retention time of analyte and 
internal standard. The chromatogram can be seen in fig. 1. The 
chromatogram of lercanidipine in plasma with five level 
concentrations which was LLOQ, Quality Control Low (QCL), Quality 
Control Medium (QCM), Quality Control High (QCH), and Upper Limit 
of Quantification (ULOQ) can be seen in fig. 2. 
 
 
Fig. 1: Lercanidipine chromatogram in blank plasma 
 
 
Fig. 2: Lercanidipine chromatogram in plasma with a concentration of LLOQ, QCL, QCM, QCH, and ULOQ 
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Table 1: Data of carry over 
Blank sample Lercanidipine carry over (%) Internal standard carry over (%) 
Blank 1 6.508 0.063 
Blank 2 10.954 0.078 
Blank 3 2.524 0.164 
Blank 4 11.996 0.071 
Blank 5 4.030 0.224 
Mean 7.202±4.168 0.120±0.071 
*Each value is represented as mean±SD 
 
Carryover 
The result showed that no carry over in plasma blanks after 
injection of the highest concentration (ULOQ) lercanidipine. The 
carryover percentage still meets the requirements for 
analytes<20% and<5% for the internal standard. The result can be 
seen in table 1. 
Calibration curve and LLOQ 
The calibration curve was linear in the concentration range of 0.025–10.0 
ng/ml with correlation coefficient (r)>0.9986. The LLOQ of lercanidipine 
was 0.025 ng/ml with CV of 9.32% and %diff between-17.74% to 6.20%. 
Accuracy, precision, and recovery 
This research performed accuracy and precision in within-run and 
between-run. The test was performed using five replicates on each of 
four concentrations of quality control samples, such as LLOQ (0.025 
ng/ml); low concentration/QCL (0.1 ng/ml); medium concentration/ 
QCM (4.0 ng/ml); and high concentration/QCH (8.0 ng/ml) for each 
time of analysis (within-run) and performed as many as three times 
the analysis of at least 2 different days (between-run). Accuracy was 
made to see the proximity of the measured concentration results in the 
analysis with the actual concentration represented by the diff% (bias) 
value, whereas the precision was performed to see the proximity 
between the repetitions of the measurement analytes represented by 
the% CV value. The method was accurate and precise because all 
values met the requirements that bias (%diff) and CV for LLOQ not 
more than 20% while other concentration levels were not more than 
15%. The result can be seen in table 2. 
Besides accuracy and precision, recovery was conducted to know 
the extraction efficiency. The recovery was calculated by 
comparing the area of analyte obtained after extraction with the 
unextracted analytical area at the same concentration. Recovery of 
lercanidipine at three levels of concentration QCL, QCM, and QCL 
was 81.89–89.98%. 
 
Table 2: Data of accuracy and precision 
 Actual Within-run  Between-run  
 Conc (ng/ml) Meas Conc (mean±SD; ng/ml) CV (%) Bias (%) Meas Conc (mean±SD; ng/ml) CV (%) Bias (%) 
 0.025 0.023±0.001 4.731 -8.99 0.026±0.0029 10.946 5.34 
 0.100 0.102±0.004 3.565 2.15 0.104±0.005 5.245 4.34 
 5.000 4.924±0.067 1.366 -1.52 4.929±0.247 5.004 -1.43 
 8.000 7.747±0.201 2.590 -3.17 7.727±0.220 2.848 -3.41 
 *Each value is represented as mean±SD of 5 replicates, CV: Coefficient of Variation 
 
Dilution integrity 
Dilution integrity was performed to ensure that dilutions during the 
analysis were accurate and reliable. The test was performed with a 
concentration above ULOQ or two QCH concentrations of 16 ng/ml, 
diluted to half (8 ng/ml) and one quarter (4 ng/ml) using a plasma 
blank. The analysis was conducted in five replicates on each dilution 
within-run and between-run and the accuracy and precision 
parameters were observed. The result showed that until one quarter 
dilution, the CV and bias (%diff) were not more than 15%, 9.458% (CV 
within-run) and 7.949% (CV between-run) with bias of 0.50% (within-
run) and-0.63% (between-run) for half dilution, while for one quarter 
dilution the CV was 4.208% (within-run) and 4.137% (between-run) 
with bias of 5.21% (within-run) and 3.42% (between-run). 
Matrix effect 
Matrix effect was conducted because the analysis of lercanidipine in 
plasma using mass spectrometry. The matrix effect describes the 
presence of other compounds outside the analyte and internal 
standard in the ionization of the analyte and the internal standard in 
ionization process. This effect was represented by the matrix factor by 
calculating the percentage between the analyte area added after the 
blank extraction process with the standard solution area. The result 
can be seen in table 3. 
 
Table 3: Data of matrix effect of lercanidipine in plasma 
Actual Conc 
(ng/ml) 




Internal standard normalized matrix factor  
Matrix factor (mean±SD; %) CV (%) 
0.100 84.19±3.64 4.32 4.53±0.26 5.68 
8.000 85.83±1.39 1.62 4.62±0.28 6.03 
 *Each value is represented as mean±SD of 5 replicates CV: Coefficient of Variation 
 
Stability 
The stability test was carried out in order to ensure that the storage 
condition and sample preparation not affecting the concentration of 
the analyte. The stability test was performed using QCL and QCH 
samples of each of the three replicates. For short-term stability tests, 
samples were stored at room temperature for 24 h.  
The results showed that lercanidipine was stable in plasma for at least 
24 h at room temperature. 
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Table 4: Short-term stability of lercanidipine in plasma 
Hour QCL 0.100ng/ml QCH 8.000 ng/ml 
Meas conc (mean±SD; ng/ml) CV (%) Bias (%) Meas conc (mean±SD; ng/ml) CV (%) Bias (%) 
0 hour 0.096±0.005 5.515 -3.52 7.396±0.390 5.272 -7.55 
6 hour 0.107±0.007 6.438 7.36 7.714±0.273 3.545 -3.58 
12 hour 0.109±0.003 2.831 9.38 7.921±0.414 5.230 -0.99 
 *Each value is represented as mean±SD of 3 replicates CV: Coefficient of Variation 
 
The study also performed long-term stability tests, in which the sample 
was stored in a freezer temperature of-20 °C in the periods of 0, 7, 14 d, 
freeze and thaw, thus post preparation stability (autosampler). The 
stability testing results showed that lercanidipine in plasma was stable 
for at least 14 d at-20 °C, after freeze-thaw for at least three cycles, and 
was stable for at least 24 h in the autosampler.  
The selected ionisation source in this research was ESI (Electrospray 
Ionization) type positive because the analyte and internal standard were 
basic therefore ionization can be done by addition of H+ion or 
protonation. The value of m/z is based on the greatest abundance in each 
value. Lercanidipine was detected at an m/z ratio of 612.18>280.27 
whereas amlodipine was detected at 409.1>238.15. The acquired m/z 
value was based on the greatest abundance in each value. Parent ion of 
lercanidipine was detected at m/z value of 612.18, then was 
fragmented into methyl-5-formyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-
dihydro-pyridine-3-carboxylate at m/z 315.0; (3.3-diphenylpropyl) 
(methyl)(2-methylprop-1-en-1-yl)amine at m/z value 298.3; and 1-[(3,3-
diphenylpropyl) (methyl) amino]-2-methylpropan-2-ol at m/z 280.27 
[7]. 
Parent ion of amlodipine 3-Ethyl-5-methyl-2-[(2-aminoethoxy) 
methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-
dicarboxylic acid at m/z value 409.1. Then this parent fragmented into 
a 3-Ethyl-5-methyl-4-(2-chlorophenyl)-2-(ethoxymethyl)-6-methyl-1, 
4-dihydropyridine-3,5-dicarboxylic acid at m/z value 377.20; ethyl 
(2E)-3-amino-2-[(2-chlorophenyl) methyl]-4-(ethenyloxy) but-2-
enoate at m/z value of 294.14; and ethyl (2E)-3-amino-2-[(2-
chlorophenyl) methyl] prop-2-enoate at an m/z value of 238.15 [8]. 
The mass spectrum of each fragmentation can be seen in fig. 3 and fig. 




Fig. 3: Lercanidipine mass spectrum and ion fragmentation 
 
 
Fig. 4: Amlodipine mass spectrum and ion fragmentation 
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Sample preparation was conducted using liquid-liquid extraction. 
This method was chosen because it cleans the analytes of many 
impurities in the plasma and can extend the life of the column 
because the impurity compound retained in the column becomes 
less. The parameters observed were the area of the resulting analyte 
and the best chromatogram peak. The optimization was carried out 
by some solvents i.e. n-hexane, ethyl acetate, a combination of n-
hexane-ethyl acetate (50:50), and dichloromethane with the addition 
of 10 times the plasma amount each. Consideration of using such 
organic solvents as extracting solutions because they are non-polar 
and the analyte also non-polar so that the analyte will be extracted 
into the organic phase (separate from the proteins in the plasma). 
The optimization results were selected based on the analytical area 
and the internal standard and chromatogram form of each 
compound. The optimum condition was obtained by the extraction 
method using a combination of n-hexane and ethyl acetate (50:50) as 
a solvent with a good chromatogram in each compound. After the 
optimum extracting solution was obtained, the optimization of 
vortex mixed and centrifugation was performed. Optimizations were 
conducted for 1, 2, and 3 min and vortexed for 5, 10, 15, and 20 min 
for centrifugation. The optimum condition was obtained on vortex 
mixed for 3 min and 20 min of centrifugation time as it produced the 
largest area, while the optimum time for evaporation of the organic 
solvent was 30 min. Based on all value results of validation that met 
the requirements of EMA Guideline on Bioanalytical Method 
Validation, 2011, it can be concluded that the developed method was 
valid. In this study, LLOQ was obtained up to 0.05 ng/ml, more 
specific than previous research. In addition, the sample preparation 
in this study was carried out by liquid-liquid extraction which was 
more economical. 
CONCLUSION 
The developed method was valid and linear in the range concentration 
of 0.025-10 ng/ml and can be applied in pharmacokinetic and 
bioequivalence studies. 
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